Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts. Show more
Location: 300 Fifth Avenue, Waltham, MA, 02451, United States | Website: https://crescentbiopharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
196.7M
52 Wk Range
$10.83 - $63.00
Previous Close
$11.72
Open
$11.86
Volume
42,060
Day Range
$11.59 - $11.92
Enterprise Value
54.89M
Cash
152.6M
Avg Qtr Burn
-6.269M
Insider Ownership
6.56%
Institutional Own.
77.39%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SQ Dalcinonacog alfa (DalcA) Details Hemophilia, Genetic disorder | Failed Discontinued | |
Marzeptacog alfa (MarzAA) Details Hemophilia, Blood disorder, Rare genetic disease | Failed Discontinued |